KR970705635A - 사람 케모킨 베타-9(Human chemokine beta-9) - Google Patents
사람 케모킨 베타-9(Human chemokine beta-9) Download PDFInfo
- Publication number
- KR970705635A KR970705635A KR1019970701144A KR19970701144A KR970705635A KR 970705635 A KR970705635 A KR 970705635A KR 1019970701144 A KR1019970701144 A KR 1019970701144A KR 19970701144 A KR19970701144 A KR 19970701144A KR 970705635 A KR970705635 A KR 970705635A
- Authority
- KR
- South Korea
- Prior art keywords
- polypeptide
- polynucleotide
- amino acid
- seq
- dna
- Prior art date
Links
- 102000019034 Chemokines Human genes 0.000 title abstract 2
- 108010012236 Chemokines Proteins 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 25
- 229920001184 polypeptide Polymers 0.000 claims abstract 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 24
- 108020004414 DNA Proteins 0.000 claims abstract 8
- 238000000034 method Methods 0.000 claims abstract 7
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 230000035772 mutation Effects 0.000 claims abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims 16
- 102000040430 polynucleotide Human genes 0.000 claims 16
- 239000002157 polynucleotide Substances 0.000 claims 16
- 150000001413 amino acids Chemical class 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000009452 underexpressoin Effects 0.000 claims 1
- 230000001018 virulence Effects 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108091026890 Coding region Proteins 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000037581 Persistent Infection Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000010188 recombinant method Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
사람 Ckβ-9 폴리펩타이드 및 이러한 케모킨 폴리펩타이드를 암호화하는 DNA(RNA) 및 재조합 기술에 의해 이러한 폴리펩타이드를 제조하는 방법이 기술되어 있다. 또한 백혈병, 종양, 만성 감염, 자가면적 질환, 섬유중 질환, 상처 치유 및 건선 치료시 이러한 Ckβ-9 폴리펩타이드를 이용하는 방법이 또한 기술되어 있다. 이러한 폴리펩타이드에 대한 길항제 및 류마치스 관절염, 자가면역 질환, 만성 염증성 질환 및 감염성 질환을 치료하기 위한 치료제로서의 이의 용도가 또한 기술되어 있다. Ckβ-9 암호화 서열중 돌연변이의 존재 및 Ckβ-9 단백질의 과-발현을 검출하는 진단 방법이 또한 기술되어 있다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 cDNA 서열을 도시한 것이며 이는 Ckβ-9의 유추된 아미노산 서열에 상응한다. 제2도는 Ckβ-9 과 에토탁신의 성숙한 펩타이드(하단)간의 아미노산 서열 상동성을 나타낸다.
Claims (20)
- (a) 서열 2에 설정된 바와 같은 -23번 아미노산에서 111번 아미노산까지를 포함하는 폴리펩타이드를 암호화하는 폴리뉴클레오타이드; (b) 서열2에 설정된 바와 같은 1번 아미노산에서 111번 아미노산까지를 포함하는 폴리펩타이드를 암호화하는 폴리뉴클레오타이드; (c) 상기 (a) 또는 (b)의 폴리뉴클레오타이드와 70% 이상의 동일하며 이에 하이브리드화할 수 있는 폴리뉴클레오타이드; 및 (d) 상기 (a), (b) 또는 (c)의 폴리뉴클레오타이드의 폴리뉴클레오타이드 단편으로 이루어진 그룹중에서 선택된 구성원을 포함하는 분리된 폴리뉴클레오타이드.
- 제1항에 있어서, DNA인 폴리뉴클레오타이드.
- 제2항에 있어서, 서열 2의 1번 아미노산에서 111번 아미노산까지를 포함하는 폴리펩타이드를 암호화하는 폴리뉴클레오타이드.
- (a) ATCC 기탁 번호 제75803호중에 포함된 DNA에의해 발현된 아미노산 서열을 갖는 성숙한 폴리펩타이드를 암호화하는 폴리뉴클레오타이드; (b) ATCC 기탁 번호 제75803호중에 포함된 DNA에 의해 발현된 아미노산 서열을 갖는 폴리펩타이드를 암호화하는 폴리뉴클레오타이드; (c) 상기 (a)의 폴리뉴클레오타이드; 및 (d) 상기 (a), (b) 또는 (c)의 폴리뉴클레오타이드의 폴리뉴클레오타이드 단편으로 이루어진 그룹중에서 선택된 구성원을 포함하는 분리된 폴리뉴클레오타이드.
- 제1항에 있어서, 서열 1에 설정된 바와 같은 1번 뉴클레오타이드에서 405번 뉴클레오타이드까지의 서열을 포함하는 폴리뉴클레오타이드.
- 제1항에 있어서, 서열 1에 설정된 바와 같은 70번 뉴클레오타이드에서 405번 뉴클레오타이드까지의 서열을 포함하는 폴리뉴클레오타이드.
- 제2항에 따른 DNA를 포함하는 벡터.
- 제7항에 따른 벡터를 사용하여 유전적으로 조작된 숙주 세포.
- 제8항에 따른 숙주 세포로부터 상기 DNA가 암호화한 폴리펩타이드를 발현시킴을 포함하는, 폴리펩타이드의 제조 방법.
- 제7항에 따른 벡터로 세포를 유전적으로 조작함을 포함하여, 폴리펩타이드를 발현시킬 수 있는 세포를 생산하는 방법.
- (i) 서열 2의 유추된 아미노산 서열을 갖는 성숙한 폴리펩타이드, 및 이의 단편, 동족체 및 유도체; 및 (ⅱ) ATCC 기탁번호 제75803호의 cDNA에 의해 암호화된 성숙한 폴리펩타이드, 및 이의 단편, 동족체 및 유도체로 이루어진 그룹중에서 선택된 구성원을 포함하는, 제1항에 따른 폴리뉴클레오타이드에 의해 암호화된 폴리펩타이드.
- 제11항에 있어서, 서열 2의 1번 아미노산에서 111번 아미노산까지를 포함하는 폴리펩타이드.
- 제11항에 따른 폴리펩타이드에 대한 수용체의 활성화를 억제하는 화합물.
- 제11항에 따른 폴리펩타이드에 대한 수용체의 활성화시키는 화합물.
- 제11항에 따른 폴리펩타이드의 치료학적 유효량을, Ckβ-9를필요로 하는 환자에게 투여함을 포함하여, 상기 환자를 치료하는 방법.
- 제15항에 있어서, 치료학적 유효량의 상기 폴리펩타이드가, 상기 폴리펩타이드를 암호화하는 DNA를 환자에게 제공하고 생체내에서 이러한 폴리펩타이드를 발현시킴에 의해 투여되는 방법.
- 제13항에 따른 화합물의 치료학적 유효량을, Ckβ-9 폴리펩타이드를 억제할 필요가 있는 환자에게 투여함을 포함하여, 상기 환자를 치료하는 방법.
- 제11항에 따른 폴리펩타이드를 암호화하는 핵산 서열중의 돌연변이를 결정함을 포함하여, 상기 폴리펩타이드의 저-발현(under-expression)과 관련된 질병 자체 또는 이러한 빌병에 걸리기 쉬운지의 여부를 진단하는 방법.
- 숙주로부터 기원한 샘플중에서 제11항에 따른 폴리펩타이드의 존재를 분석함을 포함하는 진단 방법.
- 수용체에 대한 결합을 허용하는 조건하에서, 분석적으로 검출가능한 화합물을, 이 화합물과의 결합에 반응하여 검출가능한 시그날을 제공할 수 있는 제2성분과 얀합된, 폴리펩타이드에 대한 수용체를 자체의 표면상에서 발현하는 세포와 접촉시키는 단계; 및 상기 화합물과 수용체의 상호작용으로부터 생성되는 시그날의 부재 또는 존재 여부를 검정하는 단계를 포함하는, 제11항의 폴리펩타이드에 대한 효능제 화합물 또는 길항제 화합물을 동정하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29425194A | 1994-08-23 | 1994-08-23 | |
US08/294,251 | 1994-08-23 | ||
PCT/US1995/006260 WO1996006169A1 (en) | 1994-08-23 | 1995-06-06 | Human chemokine beta-9 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR970705635A true KR970705635A (ko) | 1997-10-09 |
Family
ID=23132551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019970701144A KR970705635A (ko) | 1994-08-23 | 1995-06-06 | 사람 케모킨 베타-9(Human chemokine beta-9) |
Country Status (14)
Country | Link |
---|---|
US (3) | US6518046B1 (ko) |
EP (1) | EP0799311B1 (ko) |
JP (2) | JPH10505493A (ko) |
KR (1) | KR970705635A (ko) |
AT (1) | ATE290080T1 (ko) |
AU (1) | AU708558B2 (ko) |
CA (1) | CA2198206A1 (ko) |
DE (1) | DE69534044T2 (ko) |
DK (1) | DK0799311T3 (ko) |
ES (1) | ES2235172T3 (ko) |
MX (1) | MX9701330A (ko) |
NZ (1) | NZ288799A (ko) |
PT (1) | PT799311E (ko) |
WO (1) | WO1996006169A1 (ko) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391589B1 (en) | 1994-08-23 | 2002-05-21 | Human Genome Sciences, Inc. | Human chemokine beta-10 mutant polypeptides |
US6174995B1 (en) | 1994-08-23 | 2001-01-16 | Haodong Li | Human chemokines, CKβ4 and CKβ10/MCP-4 |
US6458349B1 (en) | 1995-06-02 | 2002-10-01 | Human Genome Sciences, Inc. | Chemokine β-4 polypeptides |
US7005509B1 (en) | 1995-02-17 | 2006-02-28 | Incyte Corporation | Chemokine PANEC-1 polynucleotides and compositions and methods related thereto |
US6290948B1 (en) | 1996-05-14 | 2001-09-18 | Smithkline Beecham Corporation | Method of treating sepsis and ARDS using chamohine beta-10 |
JP2001523946A (ja) * | 1996-10-02 | 2001-11-27 | シェーリング コーポレイション | 哺乳動物ケモカイン |
WO1998031809A1 (fr) * | 1997-01-20 | 1998-07-23 | Shionogi & Co., Ltd. | Slc humaine de chemokine cc |
WO1998056818A1 (en) * | 1997-06-11 | 1998-12-17 | Genetics Institute, Inc. | Human l105 proteins and polynucleotides encoding same |
US6084071A (en) * | 1997-06-11 | 2000-07-04 | Genetics Institute | Human L105 polypeptides and polynucleotides encoding same |
US6153441A (en) * | 1998-02-17 | 2000-11-28 | Smithkline Beecham Corporation | Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof |
AU2715700A (en) * | 1998-12-31 | 2000-07-31 | Chiron Corporation | Methods for treating cancer and for mediating chemotaxis of dendritic cells |
US6949243B1 (en) | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
CA2389979C (en) * | 1999-11-24 | 2011-08-16 | Schering Corporation | Methods of inhibiting metastasis |
US20030175801A1 (en) * | 2001-04-18 | 2003-09-18 | Dubinett Steven M. | Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals |
US20020168358A1 (en) * | 2001-04-30 | 2002-11-14 | Gladue Ronald P. | Treatment of T-cell mediated diseases |
EP1534752B1 (en) | 2002-05-01 | 2011-08-03 | Human Genome Sciences, Inc. | Antibodies that specifically bind to chemokine beta-4 |
US8795668B2 (en) * | 2005-12-23 | 2014-08-05 | The Regents Of The University Of Michigan | Methods for treating pulmonary fibrosis |
US9012419B2 (en) * | 2006-05-17 | 2015-04-21 | University Of Utah Research Foundation | Methods and compositions related to eosinophil regulation |
SG10201509499RA (en) | 2010-11-19 | 2015-12-30 | Eisai R&D Man Co Ltd | Neutralizing anti-ccl20 antibodies |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE177472T1 (de) | 1990-09-14 | 1999-03-15 | Chiron Corp | Expression von makrophagen-induzierbaren proteinen (mips) in hefezellen |
US7005509B1 (en) * | 1995-02-17 | 2006-02-28 | Incyte Corporation | Chemokine PANEC-1 polynucleotides and compositions and methods related thereto |
-
1995
- 1995-06-06 PT PT95923661T patent/PT799311E/pt unknown
- 1995-06-06 KR KR1019970701144A patent/KR970705635A/ko not_active Application Discontinuation
- 1995-06-06 CA CA002198206A patent/CA2198206A1/en not_active Abandoned
- 1995-06-06 DK DK95923661T patent/DK0799311T3/da active
- 1995-06-06 MX MX9701330A patent/MX9701330A/es unknown
- 1995-06-06 US US08/793,381 patent/US6518046B1/en not_active Expired - Lifetime
- 1995-06-06 ES ES95923661T patent/ES2235172T3/es not_active Expired - Lifetime
- 1995-06-06 AT AT95923661T patent/ATE290080T1/de active
- 1995-06-06 DE DE69534044T patent/DE69534044T2/de not_active Expired - Lifetime
- 1995-06-06 NZ NZ288799A patent/NZ288799A/xx not_active IP Right Cessation
- 1995-06-06 JP JP8508037A patent/JPH10505493A/ja not_active Ceased
- 1995-06-06 AU AU28141/95A patent/AU708558B2/en not_active Ceased
- 1995-06-06 WO PCT/US1995/006260 patent/WO1996006169A1/en active IP Right Grant
- 1995-06-06 EP EP95923661A patent/EP0799311B1/en not_active Expired - Lifetime
-
2002
- 2002-06-03 JP JP2002161804A patent/JP2003047492A/ja active Pending
- 2002-12-27 US US10/329,472 patent/US7097985B2/en not_active Expired - Fee Related
-
2005
- 2005-10-28 US US11/260,166 patent/US7198944B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2198206A1 (en) | 1996-02-29 |
AU2814195A (en) | 1996-03-14 |
US7198944B2 (en) | 2007-04-03 |
DK0799311T3 (da) | 2005-07-11 |
MX9701330A (es) | 1998-02-28 |
JPH10505493A (ja) | 1998-06-02 |
AU708558B2 (en) | 1999-08-05 |
US20060040313A1 (en) | 2006-02-23 |
US7097985B2 (en) | 2006-08-29 |
NZ288799A (en) | 1999-06-29 |
US6518046B1 (en) | 2003-02-11 |
EP0799311A1 (en) | 1997-10-08 |
ES2235172T3 (es) | 2005-07-01 |
EP0799311B1 (en) | 2005-03-02 |
DE69534044D1 (de) | 2005-04-07 |
EP0799311A4 (en) | 1998-09-30 |
JP2003047492A (ja) | 2003-02-18 |
DE69534044T2 (de) | 2005-12-29 |
WO1996006169A1 (en) | 1996-02-29 |
ATE290080T1 (de) | 2005-03-15 |
PT799311E (pt) | 2005-05-31 |
US20050244888A1 (en) | 2005-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR970705635A (ko) | 사람 케모킨 베타-9(Human chemokine beta-9) | |
DK176181B1 (da) | Et rekombinant oplöseligt fragment af alfa-subenhedpolypeptidet af human mastcelle IgE overfladereceptor samt anvendelse af samme | |
KR970701776A (ko) | 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1) | |
KR970707141A (ko) | 종양 괴사 인자-감마(Tumor necrosis factor-gamma) | |
EP0814158A3 (en) | Human C3a receptor variant; uses in diagnostics and therapeutics | |
KR970705405A (ko) | 사람 케모킨 폴리펩타이드(Human Chemokine Polypeptides) | |
NZ279963A (en) | Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946 | |
CA2067744A1 (en) | The human c3b/c4b receptor (cr1) | |
KR970700438A (ko) | 마크로파지 염증성 단백질-3,-4 및 -1감마(MACROPHAGE INFLAMMATORY PROTEINS -3,-4 AND -1sg(g)) | |
CA2247285A1 (en) | Human tumor necrosis factor delta and epsilon | |
EP1015488A4 (en) | INTERLEUKIN-17 RECEPTOR-LIKE PROTEIN | |
CA2529179A1 (en) | Recombinant adeno-associated virus vector for treatment of alzheimer disease | |
SG52789A1 (en) | The human C3B/C4B receptor (cr1) | |
EP0904369A1 (en) | Autoantigen and proteins structurally related thereto for use in immunotherapy of autoimmune diseases | |
NZ332318A (en) | Chemokine alpha 2 and it's therapeutic and diagnostic use in treating illnesses | |
WO1998006841A3 (en) | Two human nsp-like proteins | |
EP0812913A3 (en) | HR-1 receptor, a receptor of the cytokine receptors family | |
KR970704887A (ko) | 혈청 파라옥소나제 | |
KR970701724A (ko) | 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin) | |
EP0834568A3 (en) | Novel saliva binding protein | |
EA005973B1 (ru) | Применение sarp-1 для лечения и/или предупреждения склеродермии | |
JP2004533235A5 (ko) | ||
WO2002030979A3 (en) | Polypeptides homologous to thymosin, ephrin a receptors, and fibromodulin, and polynucleotides encoding same | |
CA2215350A1 (en) | Transforming growth factor alpha hii | |
KR970707155A (ko) | 사람 스탄니오칼신-알파(Human stanniocalcin-alpha) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |